{"id":{"repo_id":"ajou","oai_identifier":"oai:repository.ajou.ac.kr:201003/13074"},"canonical_url":"https://search.dev.ndltd.org/etd/ajou/oai:repository.ajou.ac.kr:201003/13074","repository":{"repo_id":"ajou","name":"Ajou University","base_url":"http://repository.ajou.ac.kr/oai/request"},"display":{"title":"Predictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer","abstract":"Purpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC. Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy. Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival. Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.","abstract_html":"Purpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC. Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy. Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival. Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.","abstract_has_math":false,"creators":["JIN, MING"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["한, 세환","대학원 의학과","201424693"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-11-30T23:41:26Z","date_published":"2016-11-30T23:41:26Z","updated_at":"2026-07-24T00:51:53Z","subjects":["neoplasms","Neoadjuvant therapy","Disease Progression"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176","000000023176"],"render_values":[{"text":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176","href":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176","code":true},{"text":"000000023176","href":null,"code":true}]}]},"links":{"outbound_url":"http://repository.ajou.ac.kr/handle/201003/13074","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["한, 세환","대학원 의학과","201424693","JIN, MING"]},{"key":"dc:creator","label":"Author","values":["JIN, MING"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2016-11-30T23:41:26Z","2016"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["neoplasms","Neoadjuvant therapy","Disease Progression"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.ajou.ac.kr/handle/201003/13074","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176","000000023176"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Purpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC. Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy. Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival. Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.","Ⅰ. INTRODUCTION 1 Ⅱ. METHODS 2 A. Study population 2 B. Staging and Treatment 2 C. Assessment of tumor response 3 D. Statistical analysis 3 Ⅲ. RESULTS 4 A. Response to anthracycline-based regimen 4 B. Response to taxane-based regimen 5 C. Pathologic response after neoadjuvant chemotherapy 8 D. Predictive factors of no response to neoadjuvant chemotherapy 8 E. Clinical outcomes 10 Ⅳ. DISCUSSION 12 Ⅴ. CONCLUSION 16 REFERENCES 17","Master"]},{"key":"dc:format","label":"Dc Format","values":["text/plain"]},{"key":"dc:title","label":"Title","values":["Predictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer","유방암 환자의 선행항암화학요법 중 유방암의 진행 예측인자에 관한 연구"]}]}],"canonical_facts":{"dc:contributor":["한, 세환","대학원 의학과","201424693","JIN, MING"],"dc:creator":["JIN, MING"],"dc:date":["2016-11-30T23:41:26Z","2016"],"dc:description":["Purpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC. Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy. Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival. Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.","Ⅰ. INTRODUCTION 1 Ⅱ. METHODS 2 A. Study population 2 B. Staging and Treatment 2 C. Assessment of tumor response 3 D. Statistical analysis 3 Ⅲ. RESULTS 4 A. Response to anthracycline-based regimen 4 B. Response to taxane-based regimen 5 C. Pathologic response after neoadjuvant chemotherapy 8 D. Predictive factors of no response to neoadjuvant chemotherapy 8 E. Clinical outcomes 10 Ⅳ. DISCUSSION 12 Ⅴ. CONCLUSION 16 REFERENCES 17","Master"],"dc:format":["text/plain"],"dc:identifier":["http://repository.ajou.ac.kr/handle/201003/13074","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176","000000023176"],"dc:language":["en"],"dc:subject":["neoplasms","Neoadjuvant therapy","Disease Progression"],"dc:title":["Predictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer","유방암 환자의 선행항암화학요법 중 유방암의 진행 예측인자에 관한 연구"],"dc:type":["Thesis","Theses"]},"updated_at":"2026-07-24T00:51:53Z"}